Abstract: ImmVira, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. Citigroup and CICC are the joint sponsors. In our previous note, we looked at the company's core product MVR-T3011, including its mechanism and clinical data, as well as its management and investor backing. In this note, we look at developments in the company's assets and the competitive setting.
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.